Literature DB >> 15632315

Hereditary hormone excess: genes, molecular pathways, and syndromes.

Stephen J Marx1, William F Simonds.   

Abstract

Hereditary origin of a tumor helps toward early discovery of its mutated gene; for example, it supports the compilation of a DNA panel from index cases to identify that gene by finding mutations in it. The gene for a hereditary tumor may contribute also to common tumors. For some syndromes, such as hereditary paraganglioma, several genes can cause a similar syndrome. For other syndromes, such as multiple endocrine neoplasia 2, one gene supports variants of a syndrome. Onset usually begins earlier and in more locations with hereditary than sporadic tumors. Mono- or oligoclonal ("clonal") tumor usually implies a postnatal delay, albeit less delay than for sporadic tumor, to onset and potential for cancer. Hormone excess from a polyclonal tissue shows onset at birth and no benefit from subtotal ablation of the secreting organ. Genes can cause neoplasms through stepwise loss of function, gain of function, or combinations of these. Polyclonal hormonal excess reflects abnormal gene dosage or effect, such as activation or haploinsufficiency. Polyclonal hyperplasia can cause the main endpoint of clinical expression in some syndromes or can be a precursor to clonal progression in others. Gene discovery is usually the first step toward clarifying the molecule and pathway mutated in a syndrome. Most mutated pathways in hormone excess states are only partly understood. The bases for tissue specificity of hormone excess syndromes are usually uncertain. In a few syndromes, tissue selectivity arises from mutation in the open reading frame of a regulatory gene (CASR, TSHR) with selective expression driven by its promoter. Polyclonal excess of a hormone is usually from a defect in the sensor system for an extracellular ligand (e.g., calcium, glucose, TSH). The final connections of any of these polyclonal or clonal pathways to hormone secretion have not been identified. In many cases, monoclonal proliferation causes hormone excess, probably as a secondary consequence of accumulation of cells with coincidental hormone-secretory ability.

Entities:  

Mesh:

Year:  2005        PMID: 15632315     DOI: 10.1210/er.2003-0037

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  24 in total

1.  Insulin secretion and insulin-producing tumors.

Authors:  Jean-Marc Guettier; Phillip Gorden
Journal:  Expert Rev Endocrinol Metab       Date:  2010-03-01

2.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.

Authors:  C A Stratakis; M A Tichomirowa; S Boikos; M F Azevedo; M Lodish; M Martari; S Verma; A F Daly; M Raygada; M F Keil; J Papademetriou; L Drori-Herishanu; A Horvath; K M Tsang; M Nesterova; S Franklin; J-F Vanbellinghen; V Bours; R Salvatori; A Beckers
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

3.  Impaired transforming growth factor-β (TGF-β) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1).

Authors:  Lucie Canaff; Jean-François Vanbellinghen; Hiroshi Kaji; David Goltzman; Geoffrey N Hendy
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

4.  [65-year old female patient with persistent hypercalcemia].

Authors:  M Wiedmann; W Kassahun; F Deckert; M Tröltzsch; M Sturmvoll; D Führer
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

5.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 6.  [Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy].

Authors:  L Fischer; A Mehrabi; M W Büchler
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

7.  Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor.

Authors:  Sahzene Yavuz; William F Simonds; Lee S Weinstein; Michael T Collins; Electron Kebebew; Naris Nilubol; Giao Q Phan; Steven K Libutti; Alan T Remaley; Manuel Van Deventer; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

Review 8.  Multiplicity of hormone-secreting tumors: common themes about cause, expression, and management.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

Review 9.  Uncoupling of secretion from growth in some hormone secretory tissues.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2014-07-08       Impact factor: 5.958

Review 10.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.